An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
NTT Research Names Dr. Al Emondi Head of Partner Strategy
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
NTT Research has appointed Dr. Al Emondi as Head of Partner Strategy to enhance growth and partnerships. Previously a Program Manager at DARPA, he significantly increased portfolio investments by $133 million and achieved five FDA approvals in neurotechnology. Emondi's leadership at NAVWAR resulted in substantial growth and numerous patents. NTT Research, established in 2019, focuses on basic research in areas such as quantum information and health informatics, with an annual R&D budget of $3.6 billion.
Positive
Dr. Emondi's appointment as Head of Partner Strategy indicates a commitment to growth and partnerships.
His track record at DARPA includes a $133 million increase in portfolio investments and five FDA approvals.
Emondi's experience in leading significant S&T initiatives at NAVWAR adds to NTT Research's credibility.
Negative
None.
Neurophysicist Experienced at Building Interdisciplinary Research Environments Joins Leadership Advisory Team
SUNNYVALE, Calif.--(BUSINESS WIRE)--
NTT Research, Inc., a division of NTT (TYO:9432), today announced it has named Dr. Al Emondi Head of Partner Strategy. An experienced organizational and technology leader, Dr. Emondi joined NTT Research in March 2022 on a contract basis as part of its leadership advisory team, with responsibilities that include growth and research partner opportunities, strategic project and program support, partner enablement and value, and research investments. Dr. Emondi is also President and CEO of Piontier, LLC, a technology development and neurotech product line consultancy. He was previously a Program Manager for the Defense Advanced Research Projects Agency (DARPA) and CTO of the U.S. Naval Information Warfare Center (NAVWAR) Atlantic. Dr. Emondi received his M.S. in Electrical Engineering and Ph.D. in neuroscience from Syracuse University.
Dr. Al Emondi, Head of Partner Strategy, NTT Research, Inc. (Photo: Business Wire)
“We’re delighted to welcome Dr. Emondi to NTT Research,” said NTT Research President and CEO Kazuhiro Gomi. “He brings a wealth of experience in strategic technology management and will play a key role as we optimize our existing partnerships and explore new areas of growth.”
While at DARPA, Dr. Emondi led the ideation, launch, team selection and management of breakthrough neurotechnology applications, growing portfolio investments by $133 million within three years and achieving five FDA approvals for Investigational Device Exemptions. As CTO of NAVWAR, Dr. Emondi defined and led its strategic research initiative to stand up an effective and credible research capability in the Atlantic region, including the organization’s first collaborative Science and Technology (S&T) Research Center. Under his leadership, research across all NAVWAR business portfolios resulted in 230 new S&T initiatives; 24 patents disclosed, filed, or issued; eight meritorious findings from the Inspector General recognizing achievements in management and leadership methodologies; and cumulative growth in S&T work of $550 million.
“With my stint at the neuroscience research bench behind me, I have spent much of my professional career building successful interdisciplinary research environments – both programs and laboratories,” said Dr. Emondi. “Motivated by creativity and driven by the challenge of identifying new technical opportunity space, I have a proven history of building successful research programs, as well as creating new technical capabilities within organizations. The opportunity to build on existing success at NTT Research is incredibly exciting.”
Since its founding in 2019, NTT Research has undertaken a wide range of joint research with academic institutions, government agencies and private research organizations, both in the U.S. and around the world. In all, the NTT ResearchPhysics & Informatics (PHI), Cryptography & Information Security (CIS) and Medical & Health Informatics (MEI) labs have initiated more than 20 joint research agreements and industrial partnerships, which are currently overseen by the three lab directors and in-house research scientists who coordinate with external principal investigators. Dr. Emondi is also being tasked with contributing to organizational strategy and fostering a team culture that maximizes creativity and innovation.
About NTT Research NTT Research opened its offices in July 2019 as a new Silicon Valley startup to conduct basic research and advance technologies that promote positive change for humankind. Currently, three labs are housed at NTT Research facilities in Sunnyvale: the Physics and Informatics (PHI) Lab, the Cryptography and Information Security (CIS) Lab, and the Medical and Health Informatics (MEI) Lab. The organization aims to upgrade reality in three areas: 1) quantum information, neuroscience and photonics; 2) cryptographic and information security; and 3) medical and health informatics. NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.
What is the significance of Dr. Al Emondi's appointment at NTT Research?
Dr. Emondi's appointment as Head of Partner Strategy is significant as it signals a focus on enhancing growth and optimizing partnerships.
What achievements does Dr. Emondi bring to NTT Research from his previous roles?
Dr. Emondi previously grew DARPA's neurotechnology portfolio by $133 million and oversaw five FDA approvals, enhancing NTT Research's strategic capabilities.
When did Dr. Al Emondi join NTT Research?
Dr. Al Emondi joined NTT Research in March 2022 on a contract basis before being appointed Head of Partner Strategy.
What role does NTT Research play within NTT?
NTT Research is a division of NTT focused on conducting basic research and advancing technologies that promote positive change, with an annual R&D budget of $3.6 billion.
What are the main research areas of NTT Research?
NTT Research focuses on quantum information, cryptography, information security, and medical and health informatics.
